

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/038475 A1

(51) International Patent Classification:

C07K 14/005 (2006.01) C07K 14/705 (2006.01)
C07K 14/08 (2006.01) A61K 35/76 (2015.01)
C12N 15/86 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2024/041779

(22) International Filing Date:

09 August 2024 (09.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/532,093 11 August 2023 (11.08.2023) US
63/540,344 25 September 2023 (25.09.2023) US

(71) Applicant: **KELONIA THERAPEUTICS, INC.**

[US/US]; Suite C, 135 William T. Morrissey Boulevard,
Boston, MA 02125 (US).

(72) Inventors: **DOBSON, Connor S.**; 1270 4th St NE,
Apt 743, Washington, DC 20002 (US). **FRIEDMAN,
Kevin M.**; 525 East 2nd Street, Boston, MA 02127 (US).
PERKINS, Molly R.; 64 Bradlee Rd., Milton, MA 02186
(US). **SAZINSKY, Stephen L.**; 58 Westland Ave., Win-
chester, MA 01890 (US).


(74) Agent: **BRYAN, Erin E.**; Morse, Bames-Brown & Pendle-
ton, P.C., CityPoint, 480 Totten Pond Road, 4th Floor,
Waltham, MA 02451 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS FOR MODIFYING CELLS

Figure 9



(57) Abstract: The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more engineered receptors to immune effector cells *in vivo*.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*